Someone forgot to tell the accused yet-to-be identified insider traders of Onyx Pharmaceuticals shares the US Securities and Exchange Commission (SEC) has been paying particularly close attention to stock activity involving biopharmaceutical companies.
Someone forgot to tell the accused yet-to-be identified insider traders of Onyx Pharmaceuticals shares the US Securities and Exchange Commission (SEC) has been paying particularly close attention to stock activity involving biopharmaceutical companies.
Indeed, over the past year, the SEC has frequently been nabbing insider traders, who apparently thought they could outwit the...
Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.
